L3VLUP
ProSign in

TMCI in the 13F filings

Treace Med Concepts Inc · CUSIP 89455T109

Sector · Medical devices and instrumentsTheme · Healthcare: biopharma and medtech· L3VLUP-definedTheme · Surgical, medical and electromedical devices
Quarter
Q4 2025Q3 2025Q2 2025Q1 2025Q3 2023Q2 2023Q1 2023Q4 2022Q3 2022Q2 2021
Quarter end
30 Jun 2023
the date the book describes
Filed
15 Aug 2023
latest of these filings; the earliest 14 Aug 2023
Managers listing it
4
at least, of 95 tracked, among listed positions
Comparable managers
93
filed both Q1 2023 and Q2 2023; 2 listed it in both
Shares listed
5,004,352
combined, among listed positions
Reported value
$128m
combined, at the quarter end

Managers listing TMCI in Q2 2023

Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q1 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.

4 of 4 holders

ActionFiling
AllianceBernstein LP3,424,231$88munder 0.1%Added+206,51115 Aug 2023 (the filing on sec.gov)
Point72 Asset Management LP1,418,544$36m0.11%Addedn.a.14 Aug 2023 (the filing on sec.gov)
Woodline Partners LP137,011$3.5munder 0.1%Newnew14 Aug 2023 (the filing on sec.gov)
PDT Partners LLC24,566$628k0.09%Trimmed-14,56314 Aug 2023 (the filing on sec.gov)

Largest increases and reductions, by shares

Q1 2023 to Q2 2023, among managers that listed it in both quarters or opened it.

Increases

Reductions

New positions and exits

At least these many: a manager is shown exiting only where its own filing shows the position gone.

New (1)

Exited (0)

No exit shown by a manager’s own filing.

Ownership over time

Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
2 in Q4 2022 to 2 in Q4 2025

Tracked managers listing it, at least.

01234Q2 2021Q3 2022Q4 2022Q1 2023Q2 2023Q3 2023Q1 2025Q2 2025Q3 2025Q4 2025
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
TMCI by quarter
QuarterHoldersReported valueBuyersSellers
Q2 20211$1.3mn.a.n.a.
Q3 20222$72mn.a.n.a.
Q4 20222$74mn.a.n.a.
Q1 20232$82mn.a.n.a.
Q2 20234$128mn.a.n.a.
Q3 20231$16mn.a.n.a.
Q1 20252$4.9m20
Q2 20251$5.3m10
Q3 20252$9.3m20
Q4 20252$4.1m810

Compare with…

Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.

TMCI and LLY →TMCI and JNJ →TMCI and VRTX →Choose a stock to compare with TMCI →

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.

Which funds own TMCI, latest filings →Back to the 13F Explorer →